Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)

Market Cap	53.32B
Revenue (ttm)	2.02B
Net Income (ttm)	-200.51M
Shares Out	227.27M
EPS (ttm)	-0.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	834,781
Average Volume	447,603
Open	237.80
Previous Close	234.40
Day's Range	222.80 - 242.80
52-Week Range	103.60 - 242.80
Beta	n/a
RSI	76.51
Earnings Date	Mar 26, 2025

About HKG:6990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1,477
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6990

Financial Performance

In 2023, HKG:6990's revenue was 1.54 billion, an increase of 91.62% compared to the previous year's 803.93 million. Losses were -522.21 million, -4.72% less than in 2022.

Financial numbers in CNY